The new antiepileptic drugs: A systematic review of their efficacy and tolerability

Epilepsia

Volumn 38, Issue 8, 1997, Pages 859-880

  Marson, A G ^a   Kadir, Z A ^a   Hutton, J L ^b   Chadwick, D W ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Gabapentin; Lamotrigine; Tiagabine; Topiramate; Vigabatrin; Zonis amide

Indexed keywords

ANTICONVULSIVE AGENT; GABAPENTIN; LAMOTRIGINE; NEW DRUG; PLACEBO; TIAGABINE; TOPIRAMATE; VIGABATRIN; ZONISAMIDE;

ATAXIA; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; EPILEPSY; FATIGUE; HUMAN; NAUSEA; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; TREATMENT OUTCOME; VERTIGO;

ACETIC ACIDS; ADOLESCENT; ADULT; AGED; AMINES; ANTICONVULSANTS; CHILD; CYCLOHEXANECARBOXYLIC ACIDS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; TRIAZINES; VIGABATRIN;

EID: 0030873963     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1997.tb01251.x     Document Type: Review

References (38)

1. Marson AG, Chadwick DW. Comparing antiepileptic drugs. Curr Opin Neurol 1996;9:103-6.
2. Marson AG, Chadwick DW. How easy Are randomized controlled trials in epilepsy to find on Medline? The sensitivity and precision of two Medline searches. Epilepsia 1996;37:377-80.
3. Ring HA, Heller AJ, Farr. In: Reynolds EH, ed. Vigabatrin: rational treatment for chronic epilepsy. J Neurol Neurosurg Psychiatry 1990;53(12):1051-5.
4. Bourgeois B, Leppik IE, Sackellares JC, et al. Felbamate: a double blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology 1993;43(4):693-6.
5. Sachdeo R, Kramer LD, Rosenberg A, Sachdeo S. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992;32(3):386-92.
6. Faught E, Sachdeo RC, Remler MP, et al. Felbamate monotherapy for partial onset seizures: an active control trial. Neurology 1993;43(4):688-92.
7. Leppik IE, Dreifuss FE, Pledger GW, et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 1991;41(11):1785-9.
8. Theodore WH, Raubertas RF, Porter RJ, et al. Felbamate: a clinical trial for complex partial seizures. Epilepsia 1991;32(3):392-7.
9. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
10. Petitti DB. Meta-analysis decision analysis and cost effectiveness analysis. In: Methods for quantitative synthesis in medicine. Oxford: Oxford University Press, 1984.
11. McCullagh P, Neider JA. Generalized linear models. 2nd ed. London: Chapman and Hall, 1989.
12. Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study: the International Gabapentin Study Group. Epilepsia 1994;35(4):795-801.
13. Sivenius J, Kalviainen R, Ylinen A, Riekkinen P. Double blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991;32(4):539-42.
14. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990;335(8698):1114-7.
15. The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993;43(11):2292-8.
16. Matsuo F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures: U.S. Lamotrigine Protocol 0.5 Clinical Trial Group. Neurology 1993;43(11):2284-91.
17. Binnie CD, Debets RM, Engelsman M, et al. Double blind crossover trial of lamotrigine (Lamictal) as add on therapy in intractable epilepsy. Epilepsy Res 1989;4(3):222-9.
18. Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989;30(3):356-63.
19. Loiseau P, Yuen AW, Duche B, Menager T, Arne Bes MC. A randomised double blind placebo controlled cross-over add on trial of lamotrigine in patients with treatment resistant partial seizures. Epilepsy Res 1990;7(2):136-45.
20. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994;35(1):113-21.
21. Schapel GJ, Beran RG, Vajda FJ, et al. Double blind, placebo controlled, cross-over study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 1993;56(5):448-53.
22. Smith D, Baker G, Davies G, Dewey M, Chadwick DW. Outcomes of add on treatment with lamotrigine in partial epilepsy. Epilepsia 1993;34(2):312-22.
23. French JA, Mosier M, Walker S, Somerville K, Sussman N, and the Vigabatrin Protocol 024 Investigative Cohort. A double-blind, placebo controlled study of vigabatrin 3 g/day in patients with uncontrolled complex partial seizures. Neurology 1996;46:54-61.
24. Grunewald RA, Thompson PJ, Corcoran R, Corden Z, Jackson GD, Duncan JS. Effects of vigabatrin on partial seizures and cognitive function. J Neurol Neurosurg Psychiatry 1994;57(9):1057-63.
25. Penry JK, Wilder BJ, Rajesh C, et al. Multicenter dose-response sstudy of vigabatrin in adults with focal (partial) epilepsy. Epilepsia 1993;34(suppl 6):67. Abstract (Hoechst Marrion Roussel).
26. Schmidt D, Jacob R, Loiseau P, et al. Zonisamide for add on treatment of refractory partial epilepsy: a European double blind trial. Epilepsy Res 1993;15(1):67-73.
27. Wilder BJ, Ramsay RE, Guterman A. A double-blind multicenter placebo-controlled study of the efficacy and safety of zonisamide in the treatment of complex partial seizures in medically refractory patients. Internal report of the Dianippon Pharmaceutical Co., 1986.
28. Chadwick D, Lieberman DB, Sauermann N, Alexandir J, Garofalo E, and the Gabapentin in Generalized Seizures Study Group. Gabapentin in generalized seizures (1996). Epilepsy Res 1996;25:191-7.
29. Chiron C, Dumas C, Dulac O, et al. Vigabatrin versus hydrocortisone as first-line monotherapy in infantile spasms due to tuberous sclerosis. Epilepsia 1995;(36 suppl 3):S265.
30. Spilker B, Segreti A. Validation of the phenomenon of regresssion of seizure frequency in epilepsy. Epilepsia 1984;25(4):443-9.
31. Pocock SJ. Clinical trials: a practical approach. New York: John Wiley, 1983.
32. Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991;10:1677-77.
33. Willmore JL. Depakote adjunctive therapy in the treatment of partial seizures. Epilepsia 1995;36(suppl 3):S66.
34. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;(345):476-9.
35. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313(3):145-51.
36. MacDonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995;36(suppl 2):S2-12.
37. Sackett DL, Haynes RB, Guyatt G, Tugwell P, eds. Clinical epidemiology: a basic science for clinical medicine. 2nd ed. Boston: Little, Brown, 1991:227.
38. Commission on Antiepileptic Drugs of the International League Against Epilepsy. Guidelines for antiepileptic drug trials in children. Epilepsia 1994;35(1):94-100.